Remove 2023 Remove Patent Remove Patent Application
article thumbnail

USPTO Presents AI Strategy as AI Patent Applications Soar by 33%

IP Watchdog

Patent and Trademark Office (USPTO) today released an official Artificial Intelligence Strategy aimed at outlining the challenges faced by the Office both internally and externally, as the reach of AI impacts all aspects of innovation and society.

article thumbnail

Microsoft Filed Patent Application on Method for Eliminating Artificial Intelligence Hallucinations

JD Supra Law

Patent Application No. 18/140,658, entitled “Interacting with a Language Model using External Knowledge and Feedback,” in April 2023. The application published on October 31, 2024, and became available for public inspection. It filed U.S. By: Robinson+Cole Data Privacy + Security Insider

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Patent Application for Gilead’s Lenacapavir Opposed: Saving Generics of HIV Drugs?

SpicyIP

The Indian Patent Office (IPO) is set to hear objections against Gilead Sciences’ patent claims for Lenacapavir, an HIV drug. This situation highlights the ongoing struggle between patent protections and access to essential medicines. The looming threat is the pending patent applications by Gilead in India.

article thumbnail

The UPC's first decision on infringement by equivalence (Plant-e v Bioo, UPC_CFI_239/2023)

The IPKat

In Plant-e v Bioo the UPC provided its first decision addressing the doctrine of equivalents in patent infringement proceedings ( UPC_CFI_239/2023 ). Legal background: Equivalence around Europe The Unified Patent Court Agreement (UPCA) contains no specific provisions on the doctrine of equivalence.

article thumbnail

Patent Grant Total 2023

Patently-O

by Dennis Crouch The US Patent and Trademark Office (USPTO) issued a total of 312,100 utility patents in the calendar year 2023. This marks the fourth consecutive year of decline in the number of issued patents. In fact, numbers from US-applicants increased over the past year.

Patent 109
article thumbnail

Plausibility as a moving target: Phase III clinical trial results sink second medical use patent (T 0816/22)

The IPKat

The Board of Appeal decision in T 0816/22 considered whether post-published phase III clinical trial data showing lack of efficacy can invalidate a second medical use patent that appeared plausible based on the data in the application as filed.

Patent 105
article thumbnail

Arcturus Therapeutics Inc v. Assistant Controller: The Courts Remind the Patent Office to Give Reasons

SpicyIP

The Controller had rejected a patent application by Arcturus Therapeutics for the applicants inability to file its second written submission on time. Also, what does this tell about the quality of patent grant/ rejection orders? Her previous posts can be accessed here.

Patent 59